Editorials Published July 1, 2001 - June 30, 2004

Editorials Published July 1, 2001 - June 30, 2004

Berry, J.D. Focus on Filamentous Phage Biology, The Germinal Centre Newsletter, Summer 2004.

Chan C and Zhanel GG. Myths and reality in the treatment of lower respiratory tract infections. The Chronicle of Cardiovascular and Internal Medicine 2001;October 8-13.

Chan CKN, Shibl A, Memish Z and Zhanel GG. Community acquired pneumonia (CAP): An update. Journal of Chemotherapy 2001;13(Suppl 1):23-27.

Embree JE. Assessing immunization programs. Can J Infect Dis 13:224-225, 2002.

Embree JE. Ethics in research: Immunization and autism links. Paediatr & Child Health 9:373-372, 2004.

Embree JE. Immunization and autism links: Ethics in research. Can J Infect Dis 15: 73-74, 2004.

Embree JE. Reflections. Can J Infect Dis 12:269-270, 2001.

GinAS and Zhanel GG. Antibiotic resistance: Playing the end game. Canadian Pharmaceutical Journal 2001;6:2-8.

Hammond, GW. Editorial: Immunization Must Be Safe or We'll All Be Sorry. Can J. Inf. Dis. Vol 12 No 1 January/February 2001, 11-12.

Hook EW, Peeling RW. Syphilis control: a continuing challenge. N Eng J Med 351:122-124, 2004.

Khaliq Y and Zhanel GG. Fluoroquinolone-induced tendinopathy: A critical review of the literature. Clinical Infectious Diseases 2003;36:1404-1410.

Law BJ. Chickenpox vaccination, not chickenpox should be routine for Canadian children. CMAJ 2001; 164:1454-5.(Editorial requested by the editors of CMAJ).

MacDonald N, Embree JE, Access to vaccines: A call to action. Can J Infect Dis 14:9-10, 2003 and Paediatrics and Child Health 8:11-12, 2003.

Markowsky MJ, Smith KK, Ariano RE, Zhanel GGGinAS. An assessment of vancomycin use in 2 tertiary care hospitals. Canadian Journal of Hospital Pharmacy 2004;57:150-157.

Nicolle, L.E. A new society (editorial) Can Jour Infect Dis 2002; 13:280-281.

Nicolle, L.E. A SARS Commentary (editorial) Can Jour Infect Dis 2003; 14:145-146.

Nicolle, L.E. Experiencing West Nile virus (editorial). Can Jour Infect Dis 2003; 14:75-76

Nicolle, L.E. Food for Thought (editorial). Can Jour Infect Dis 2002; 13:155-156.

Nicolle, L.E. Infection control in acute care facilities: Evidence based patient safety (editorial). Can J Infect Dis 2001; 12:131-132.

Nicolle, L.E. Rabies: Still with us (editorial) Can Jour Infect Dis 2002; 13:83-84.

Nicolle, LE. SARS Safety and Science (editorial) Can Jour Anaesthesia 2003; 50: 983-988.

Nicolle, LE. Smallpox 2003 (editorial) Can Jour Infect Dis 2003; 14:247-248.

Nicolle, LE. Witnesses (editorial) Can Jour Infect Dis 2003; 14: 310.

Noreddin A and Zhanel GG. Pharmacokinetics and pharmacodynamics of respiratory fluoroquinolones. Current Opinions in Pharmacology 2001;1(5):459-463.

Rzeszutek M, Wierzbowski A, Conly J, Bishai W, Hoban D and Zhanel GG. A Review of Clinical Failures Involving Macrolide-Resistant Streptococcus pneumoniae. International Journal of Antimicrobial Agents 2004;24:95-104.

Sande MA, Ronald A. Treatment of HIV/AIDS: Do The Dilemmas Only Increase? JAMA. 2004 July 14;292(2):266-268.

Smith HJ, Nichol K, Hoban DJ and Zhanel GG. Stretching the mutant prevention concentration (MPC) beyond its limits. Journal of Antimicrobial Chemotherapy 2003;51(6):1323-1325.

Smith HJ, Nichol KA, Hoban DJ and Zhanel GG. Dual activity of fluoroquinolones against Streptococcus pneumoniae: The facts behind the claims. Journal of Antimicrobial Chemotherapy 2002;49:893-895.

Smith HJ, Nichol KA, Hoban DJ and Zhanel GG. Dual activity of fluoroquinolones against Streptococcus pneumoniae: The facts behind the claims. Journal of Antimicrobial Chemotherapy 2003;51(2):63-67 (Reply to letter).

Wang, G. ASM News – Journal Highlights of “ Detection in Escherichia coli of the genes encoding the major virulence factors, the genes defining the O157:H7 serotype, and components of the type 2 Shiga toxin family by multiplex PCR.” Vol 68 (12): 619, Dec. 2002.

Zhanel GG and Hoban DJ. Ketolides in the treatment of respiratory infections. Expert Opinion in Pharmacotherapy 2002;3(3):277-297.

Zhanel GG and Noreddin AM. Fluoroquinolone AUIC breakpoints and the link to bacterial killing rates: In vitro models. Annals of Pharmacotherapy 2003;37:1331-1334.

Zhanel GG and Rubinstein E. Extended release ciprofloxacin (XR). Invited commentary. Drugs Aging 2004; 21(1); 65-66.

Zhanel GG, Dueck M, Hoban DJ, Vercaigne L, Embil J, Gin AS, Karlowsky JA. Macrolides and Ketolides: A review focusing on respiratory infections. Drugs 2001;61 (4):443-498.

Zhanel GG, Embil J. Tendinopathy and fluoroquinolones: What is the risk ? Journal of Respiratory Diseases 2004;25:227 (invited letter).

Zhanel GG, Ennis K, Vercaigne L, Gin AS, Embil J, and Hoban DJ. Critical review of fluoroquinolones: Focus on respiratory infections. Drugs 2002;62(1):13-59.

Zhanel GG, Hisanaga T, Nichol K, Wierzbowski A and Hoban DJ. Emerging Treatments for Macrolide Resistant Bacteria. Expert Opinion on Emerging Drugs 2003;8:297-321.

Zhanel GG, Hoban DJ and Chan CK. Resistance to levofloxacin and failure of pneumococcal pneumonia. New England Journal of Medicine 2002;347:66.

Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Karlowsky J, Embil J, Gin AS and Hoban DJ. The glycylcyclines: A critical review. Drugs 2004;64(1);63-88.

Zhanel GG, Schroeder K, Vercaigne L, Gin AS, Embil J and Hoban DJ. A critical review of oxazolidinones: A replacement for glycopeptides? Canadian Journal of Infectious Diseases 2001;12(6):379-90.

Zhanel GG, Walters M, Noreddin A, Vercaigne L, Wierzbowski A, Embil J, Gin AS and Hoban DJ. The ketolides: A critical review. Drugs 2002; 62(12):1771-1804.

Zhanel GG, Wierzbowski A, Hisanaga T and Hoban DJ. The use of ketolides in the treatment of upper respiratory tract infections Clinical Infectious Diseases Reports 2004;6:191-199.

Zhanel GG. Cephalosporins in URTI’s: Targeting the common pathogens. Canadian Journal of Diagnosis 2002; March (Supplement):1-9.

Zhanel GG. In-vitro activity of garenoxacin, a novel des-(F) 6 fluoroquinolone. Clinical Microbiology Newsletter 2004;2:3-11.

Zhanel GG. Pharmacokinetic and pharmacodynamic factors when selecting antibiotic therapy: Focus on respiratory infections. Current Infectious Disease Reports: Antimicrobial Agents 2001;3:29-34.

Zhanel GG. Regional considerations in the management of anthrax exposure and infection. Drugs and therapy perspectives 2001;17 (24):10 (invited commentary).

Zhanel GG. The role of macrolides in the treatment of community acquired respiratory illness. Medical Tribune 2003;2:1-6.